Search Result

Isoforms Recommended:	ERK2

Results for "

ERK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Autophagy (3) Bombesin Receptor (1) Casein Kinase (1) CDK (2) Dengue virus (1) ERK (36) Flavivirus (1) FLT3 (2) GPR35 (1) GSK-3 (4) Interleukin Related (1) JNK (1) MAPKAPK2 (MK2) (2) MEK (4) Neurotensin Receptor (1) Organoid (3) PDGFR (1) Raf (2) VEGFR (1) Wnt (3) β-catenin (3)
By Research Areas:	Cancer (33) Cardiovascular Disease (1) Inflammation/Immunology (6) Metabolic Disease (5) Neurological Disease (4)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14178A

(R)-VX-11e

ERK Others

(R)-VX-11e (Compound 1) is an ERK2 inhibitor .
HY-161363

ERK2 allosteric-IN-1

ERK Metabolic Disease Cancer

ERK2 allosteric-IN-1 (compound 1) is a selective and allosteric ERK2 inhibitor with the IC₅₀ of 11 μM .
HY-112300

ERK2 IN-1

ERK Cancer

ERK2 IN-1 is a selective ERK2 inhibitor with an IC₅₀ of 7 nM .
HY-18849

ERK2-IN-3

ERK2-IN-3 (compound 2) is a inhibitor of ERK2, and inhibits Erk2 ^WT and Erk2 ^DS1 activation loop phosphorylation, with IC₅₀ of 5 μM and 42 nM, respectively .

(R)-VX-11e	ERK	Others
(R)-VX-11e (Compound 1) is an ERK2 inhibitor .

ERK2 allosteric-IN-1	ERK	Metabolic Disease Cancer
ERK2 allosteric-IN-1 (compound 1) is a selective and allosteric *ERK2* inhibitor with the IC₅₀ of 11 μM .

ERK2 IN-1	ERK	Cancer
ERK2 IN-1 is a selective *ERK2* inhibitor with an IC₅₀ of 7 nM .

ERK2-IN-3
ERK2-IN-3 (compound 2) is a inhibitor of *ERK2, and inhibits Erk2* ^WT and Erk2 ^DS1 activation loop phosphorylation, with IC₅₀ of 5 μM and 42 nM, respectively .

HY-121280

ERK2-IN-4	ERK	Cancer
ERK2-IN-4 (Compound 6o) is an effective and selective *ERK2* inhibitor with a K_i of 0.006 μM. ERK2-IN-4 inhibits the ERK signaling pathway and can be used in cancer research .

HY-142433

ERK1/2 inhibitor 7

ERK Cancer

ERK1/2 inhibitor 7 is a potent ERK inhibitor with an IC₅₀ of 0.94 nM for ERK2 (WO2021110168A1, WX006) .
HY-142437

ERK1/2 inhibitor 8

ERK Cancer

ERK1/2 inhibitor 8 is a potent ERK inhibitor with an IC₅₀ of 0.48 nM for ERK2 (WO2021110168A1, WX007) .

ERK1/2 inhibitor 7	ERK	Cancer
ERK1/2 inhibitor 7 is a potent *ERK* inhibitor with an IC₅₀ of 0.94 nM for ERK2 (WO2021110168A1, WX006) .

ERK1/2 inhibitor 8	ERK	Cancer
ERK1/2 inhibitor 8 is a potent *ERK* inhibitor with an IC₅₀ of 0.48 nM for ERK2 (WO2021110168A1, WX007) .

HY-P5440

ERKtide	ERK	Others
ERKtide is a biological active peptide. (ERKtide is a peptide substrate for ERK2. Extracellular regulated protein kinase 2 (ERK2) is a eukaryotic protein kinase whose activity is regulated by mitogenic stimuli.)

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of *ERK2* by MEK1 with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-18932

DEL-22379 1 Publications Verification	ERK Apoptosis	Cancer
DEL-22379 is an ERK dimerization Inhibitor. DEL-22379 readily binds to ERK2 with a K_d estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. ERK2 dimerization is progressively inhibited with an IC₅₀ of ~0.5 μM.

HY-111483A

Tizaterkib (hexanedioic acid)

ERK Cancer

Tizaterkib hexanedioic acid (example 18) is a potent and selective ERK2 inhibitor, with an IC₅₀ of 0.6 nM .

Tizaterkib (hexanedioic acid)	ERK	Cancer
Tizaterkib hexanedioic acid (example 18) is a potent and selective *ERK2* inhibitor, with an IC₅₀ of 0.6 nM .

HY-15816A

Ulixertinib hydrochloride 20+ Cited Publications BVD-523 hydrochloride; VRT752271 hydrochloride	ERK	Cancer
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of *ERK1/2* kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line ^[2].

HY-15816

Ulixertinib 20+ Cited Publications BVD-523; VRT752271	ERK	Cancer
Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of *ERK1/2* kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line ^[2].

HY-N0590

Corynoxeine 4 Publications Verification	ERK	Cardiovascular Disease
Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent *ERK1/ERK2* inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.

HY-15947

Ravoxertinib 40+ Cited Publications GDC-0994	ERK	Cancer
Ravoxertinib (GDC-0994) is an orally active *ERK* kinase inhibitor with an IC₅₀ of 6.1 nM and 3.1 nM for *ERK1* and *ERK2*, respectively.

HY-151367

SHR2415	ERK	Cancer
SHR2415 is a highly potent, selective and orally active *ERK1/2* inhibitor. SHR2415 has inhibition activity for ERK1 and ERK2 with IC₅₀ values of 2.8 nM and 5.9 nM, respectively. SHR2415 exhibits high potency with an IC₅₀ value of 44.6 nM in Colo205 cells. SHR2415 can be used for the research of cancer .

HY-15947A

Ravoxertinib hydrochloride 40+ Cited Publications GDC-0994 hydrochloride	ERK	Cancer
Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for *ERK* kinase activity with IC₅₀ of 6.1 nM and 3.1 nM for *ERK1* and *ERK2*, respectively.

HY-111483

Tizaterkib 2 Publications Verification AZD0364	ERK	Cancer
Tizaterkib (AZD0364) is a potent and selective *ERK2* inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC₅₀ of 0.6 nM.

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[2].

HY-153350

ERK-IN-7

ERK Cancer

ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent ERK inhibitor with IC₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively .
HY-133084

ERK-IN-2

ERK Cancer

ERK-IN-2 is a ERK2 inhibitor with an IC₅₀ value of 1.8 nM. ERK-IN-2 might lead to off-target toxicity and/or off-target activity at dose >10 μM .

ERK-IN-7	ERK	Cancer
ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent *ERK* inhibitor with IC₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively .

ERK-IN-2	ERK	Cancer
ERK-IN-2 is a *ERK2* inhibitor with an IC₅₀ value of 1.8 nM. ERK-IN-2 might lead to off-target toxicity and/or off-target activity at dose >10 μM .

HY-N1374

Magnolin 1 Publications Verification	ERK	Inflammation/Immunology
Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of *ERK1* and *ERK2* with IC₅₀s of 87 nM and 16.5 nM, respectively.

HY-108330

AG126 2 Publications Verification Tyrphostin AG126	ERK	Inflammation/Immunology
AG126 is a tyrosine kinase inhibitor, can inhibit the phosphorylation of *ERK1* and *ERK2* at 25-50 μM. AG126 can be used in meiosis, mitosis, and postmitotic research ^[2] .

HY-112287

ERK1/2 inhibitor 1 4 Publications Verification	ERK	Cancer
ERK1/2 inhibitor 1 is a potent, orally bioavailable *ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC₅₀* of 3.0 nM against ERK1 and ERK2, respectively .

HY-133084A

ERK-IN-2 free base	ERK	Cancer
ERK-IN-2 free base is a *ERK2* inhibitor with an IC₅₀ value of 1.8 nM. ERK-IN-2 free base might lead to off-target toxicity and/or off-target activity at dose >10 μM .

HY-50846

SCH772984 115+ Cited Publications	ERK	Cancer
SCH772984 is a highly selective and ATP-competitive *ERK* inhibitor, with IC₅₀s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-naïve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations .

HY-12275

FR 180204 15+ Cited Publications	Flavivirus Dengue virus ERK Apoptosis	Cancer
FR 180204 is an ATP-competitive and selective *ERK* inhibitor. FR 180204 inhibits *ERK1* and *ERK2* with IC₅₀s of 0.51 μM (K_i=0.31 μM) and 0.33 μM (K_i=0.14 μM), respectively .

HY-13076

CHIR-98014 3 Publications Verification	GSK-3	Metabolic Disease
CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC₅₀s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.

HY-131249

MK2-IN-3 2 Publications Verification	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 is a potent and selective inhibitor of **MAPKAP-K2 (MK-2), with an IC₅₀** of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC₅₀s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC₅₀s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo .

HY-101494

Temuterkib 20+ Cited Publications LY3214996	ERK	Cancer
Temuterkib (LY3214996) is a highly selective inhibitor of *ERK1* and *ERK2, with IC₅₀* of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

HY-100851A

LY-272015 hydrochloride
LY-272015 hydrochloride is an orally active, specific 5-HT_2B receptor antagonist. LY-272015 hydrochloride completely inhibits the phosphorylation of ERK2 induced by 5-HT or BW723C86. LY-272015 hydrochloride is antihypertensive in Deoxycorticosterone Acetate (DOCA)-salt-hypertensive rats ^[2].

HY-113592

ERK-IN-4	ERK	Cancer
ERK-IN-4 is an *ERK* inhibitor binds preferentially to ERK2 with a K_d of 5 μM. ERK-IN-4 specificity inhibits ERK Rsk-1 and Elk-1 phosphorylation. ERK-IN-4 has little effect on ERK protein phosphorylation by its upstream activator MEK1/2 .

HY-P10074

TAT-MEK1	ERK	Inflammation/Immunology
TAT-MEK1 is an inhibitor ofERK2, consisting of TAT and MEK1 (N-terminal), TAT (YGRKKRRQRRR) derived from human immunodeficiency (HIV-1) transcriptional trans activator (TAT), is a cell-penetrating peptide. TAT-MEK1 IC₅₀ in vitro for ERK2 is 29 μM ^[2].

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active *MEK1/2* kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 .

HY-114491

Rineterkib	ERK Raf	Cancer
Rineterkib (compound B) is an orally available *ERK1* and *ERK2* inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF ^[2].

HY-114491A

Rineterkib hydrochloride	ERK Raf	Cancer
Rineterkib hydrochloride (compound B) is an orally available *ERK1* and *ERK2* inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF ^[2].

HY-18285

Longdaysin	Casein Kinase ERK CDK	Cancer
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and *ERK2* with IC₅₀s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively ^[2].

HY-15496

E6201 ER-806201	MEK FLT3	Cancer
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC₅₀ value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC₅₀ value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC₅₀ value of 19 nM. Anti-tumor and anti-psoriasis efficacy ^[2].

HY-10182

Laduviglusib Maximum Cited Publications 141 Publications Verification CHIR-99021; CT99021	Organoid GSK-3 Wnt β-catenin Autophagy	Metabolic Disease Cancer
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy ^[2] .

HY-10182B

Laduviglusib trihydrochloride Maximum Cited Publications 141 Publications Verification CHIR-99021 trihydrochloride; CT99021 trihydrochloride	Organoid GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy ^[2] .

HY-10182A

Laduviglusib monohydrochloride Maximum Cited Publications 141 Publications Verification CHIR-99021 monohydrochloride; CT99021 monohydrochloride	Organoid GSK-3 Wnt β-catenin Autophagy	Cancer
Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy ^[2] .

HY-12843

Bohemine 1 Publications Verification	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits *ERK2* with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities ^[2].

HY-112457

MK2-IN-3 hydrate 2 Publications Verification	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive **MAPKAP-K2 (MK-2) inhibitor with an IC₅₀** of 0.85 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC₅₀=0.21 μM), MK-5 (IC₅₀=0.081 μM), ERK2 (IC₅₀=3.44 μM), MNK1(IC₅₀=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2 .

HY-150700

RLX-33	ERK	Metabolic Disease
RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC₅₀ values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome .

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer ^[2]

HY-W010907

Pamoic acid disodium	GPR35 ERK	Neurological Disease
Pamoic acid disodium is a potent GPR35 agonist with an EC₅₀ value of 79 nM. Pamoic acid disodium induces GPR35 internalization and activates *ERK1/2* with EC₅₀ values of 22 nM and 65 nM, respectively. Pamoic acid disodium potently recruits β-arrestin2 to GPR35 and has an antinociceptive effect .

HY-137322

THX-B	Neurotensin Receptor	Neurological Disease Metabolic Disease
THX-B is a potent and non-peptidic p75 ^NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders ^[2] .

Cat. No.	Product Name	Type

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF ^[2].

Cat. No.	Product Name	Target	Research Area

HY-P1342

Prosaptide Tx14(A) 1 Publications Verification	Peptides	Neurological Disease
Prosaptide Tx14(A), a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC₅₀s of 5 and 7 nM, respectively. Prosaptide Tx14(A) increases both ERK1 and ERK2 phosphorylation in Schwann cells ^[2].

HY-P5507

ERK2 Substrate ERKtide	Peptides	Others
ERK2 Substrate (Erktide) is a biological active peptide. (Erktide is a peptide substrate for ERK2 (extracellular regulated protein kinase 2) whose activity is regulated by mitogenic stimuli.)

HY-P3992

5-FAM-Dyrktide

Peptides Others

5-FAM-Dyrktide is a 5-FAM labeled Dyrktide. Dyrktide, a substrate, is efficiently phosphorylated by DYRK1A (K_m=35 μM) but not by ERK2 ^[2].

HY-P5440

ERKtide	ERK	Others
ERKtide is a biological active peptide. (ERKtide is a peptide substrate for ERK2. Extracellular regulated protein kinase 2 (ERK2) is a eukaryotic protein kinase whose activity is regulated by mitogenic stimuli.)

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of *ERK2* by MEK1 with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-P1342A

Prosaptide Tx14(A) TFA	Peptides	Neurological Disease
Prosaptide Tx14(A) TFA, a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC₅₀s of 5 and 7 nM, respectively. Prosaptide Tx14(A) TFA increases both ERK1 and ERK2 phosphorylation in Schwann cells ^[2].

HY-P10074

TAT-MEK1	ERK	Inflammation/Immunology
TAT-MEK1 is an inhibitor ofERK2, consisting of TAT and MEK1 (N-terminal), TAT (YGRKKRRQRRR) derived from human immunodeficiency (HIV-1) transcriptional trans activator (TAT), is a cell-penetrating peptide. TAT-MEK1 IC₅₀ in vitro for ERK2 is 29 μM ^[2].

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer ^[2]

Species:	Human (2) Mouse (2)
Tag:	His (3) Tag Free (1) GST (1) Flag (1)
Source:	Sf9 insect cells (3) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P75223

	ERK2 Protein, Human (sf9, His) Mitogen-activated protein kinase 1; MAPK 1; ERT1; ERK-2; p42-MAPK	Human	Sf9 insect cells
	ERK2 Protein, a key component of the MAPK/ERK cascade, regulates diverse cellular processes such as transcription, translation, mitosis, apoptosis, endosomal dynamics, and Golgi apparatus fragmentation. Through phosphorylation, it modulates substrates including transcription factors, cytoskeletal elements, apoptosis regulators, translation regulators, protein kinases, and phosphatases. ERK2 Protein, Human (sf9, His) is the recombinant human-derived ERK2 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of ERK2 Protein, Human (sf9, His) is 360 a.a., with molecular weight of ~42 kDa.

HY-P702735

	MAPK1 Protein, Human (Flag, His) MAPK1; mitogen-activated protein kinase 1; PRKM1, PRKM2; ERK; ERK2; MAPK2; p41mapk; ERK-2; MAPK 2; p42-MAPK; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; protein tyrosine kinase ERK2; mitogen-activated protein kinase 2; extracellular signal-regulated kinase 2; p38; p40; p41; ERT1; PRKM1; PRKM2; P42MAPK	Human	E. coli

HY-P74168

	ERK2 Protein, Mouse (sf9) Mitogen-activated protein kinase 1; MAPK 1; ERT1; ERK-2; p42-MAPK	Mouse	Sf9 insect cells
	ERK2 protein is an essential serine/threonine kinase in the MAP kinase pathway and cooperates with MAPK1/ERK2 in the complex MAPK/ERK cascade. Stimulated by KIT and KITLG/SCF, this pathway is central to cellular function, affecting growth, adhesion, survival, and differentiation through transcription, translation, and cytoskeletal regulation. ERK2 Protein, Mouse (sf9) is the recombinant mouse-derived ERK2 protein, expressed by Sf9 insect cells , with tag free. The total length of ERK2 Protein, Mouse (sf9) is 358 a.a., with molecular weight of ~37 kDa.

HY-P74167

	ERK2 Protein, Mouse (sf9, His-GST) Mitogen-activated protein kinase 1; MAPK 1; ERT1; ERK-2; p42-MAPK	Mouse	Sf9 insect cells
	ERK2 protein is an essential serine/threonine kinase in the MAP kinase pathway and cooperates with MAPK1/ERK2 in the complex MAPK/ERK cascade. Stimulated by KIT and KITLG/SCF, this pathway is central to cellular function, affecting growth, adhesion, survival, and differentiation through transcription, translation, and cytoskeletal regulation. ERK2 Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived ERK2 protein, expressed by Sf9 insect cells , with N-GST, N-His labeled tag. The total length of ERK2 Protein, Mouse (sf9, His-GST) is 358 a.a., with molecular weight of ~60 kDa.

Cat. No.	Product Name	Application	Reactivity

HY-P80394

ERK2 Antibody	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse, Rat
ERK2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 41 kDa, targeting to ERK2. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P81156

*phospho-ERK1 + 2 (Thr183/Tyr185) Antibody* ERK1 + ERK2 (phospho Thr183/Tyr185); phospho-ERK1/MAPK-1/2(Thr183/Tyr185); ERK 1; ERK 2; ERK-2; ERK1; ERK2; ERT1; ERT2; Extracellular signal regulated kinase 1; Extracellular signal regulated kinase 1; Extracellular signal regulated kinase 2; Extracellular signal regulated kinase 2; Extracellular signal-regulated kinase 2; HS44KDAP; HUMKER1A; Insulin stimulated MAP2 kinase; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; MAP kinase isoform p44; MAPK 1; MAPK 2; MAPK1; MAPK2; MGC20180; Microtubule associated protein 2 kinase; Mitogen activated protein kinase 1; Mitogen activated protein kinase 1; Mitogen activated protein kinase 2; Mitogen-activated protein kinase 1; Mitogen-activated protein kinase 2; MK01_MOUSE; p38; p40; p41; p41mapk; p42 MAPK; p42-MAPK; p42MAPK; p42MAPK; p44 ERK1; p44 MAPK; p44ERK1; p44ERK1; p44MAPK; p44MAPK; PRKM 1; PRKM 1; PRKM 2; PRKM 2; PRKM1; PRKM2; Protein kinase mitogen activated 1; Protein kinase mitogen activated 1; Protein kinase mitogen activated 2; Protein kinase mitogen activated 2; Protein tyrosine kinas.	WB; ELISA; IHC-P; IHC-F; ICC; IF	Human, Mouse(predicted: Rat, Chicken, Dog, Cow, Horse, Rabbit, Guinea Pig)
phospho-ERK1 + 2 (Thr183/Tyr185) Antibody is an unconjugated, approximately 42/44 kDa, rabbit-derived, anti-phospho-ERK1 + 2 (Thr183/Tyr185) polyclonal antibody. phospho-ERK1 + 2 (Thr183/Tyr185) Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF expriments in human, mouse, and predicted: rat, chicken, dog, cow, horse, rabbit, guinea pig background without labeling.

HY-P80392

Erk1 (pT202/pY204)+Erk2 (pT185/pY187) Antibody (YA455)	WB, IP, IHC-P	Human
Erk1 (pT202/pY204)+Erk2 (pT185/pY187) Antibody (YA455) is a non-conjugated and Rabbit origined monoclonal antibody about 41/43 kDa, targeting to Erk1 (pT202/pY204) + Erk2 (pT185/pY187). It can be used for WB,IP,IHC-P assays with tag free, in the background of Human.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks